OFIX
Orthofix Medical Inc.
OFIX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over OFIX overall, supported by stronger fundamentals and stronger modeled upside.
OFIX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
OFIX's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OFIX PE Valuation
OFIX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
OFIX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect OFIX's losses to shrink, with revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over OFIX on the outlook, with more favorable revenue expectations.
OFIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.11 | +$1.93 |
| Q2 2026 | -$1.53 | +$1.65 |
| Q1 2026 | -$1.50 | +$2.20 |
| Q4 2025 | -$2.33 | +$0.97 |
| Q3 2025 | -$3.04 | +$0.07 |
| Q2 2025 | -$3.18 | -$0.01 |
| Q1 2025 | -$3.70 | -$0.34 |
| Q4 2024 | -$3.30 | +$0.82 |
OFIX is still losing money, but far less than before: $1.11 per share over the past year, against $4.12 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over OFIX on earnings quality, reporting a profit while its opponent remains loss making.
OFIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $207.9M | +1.1% |
| Q2 2026 | $210.9M | +3.8% |
| Q1 2026 | $196.7M | +1.6% |
| Q4 2025 | $219.9M | +2% |
| Q3 2025 | $205.6M | +4.6% |
| Q2 2025 | $203.1M | +2.3% |
| Q1 2025 | $193.6M | +2.7% |
| Q4 2024 | $215.7M | +7.6% |
OFIX's revenue has grown year over year for 15 quarters in a row: $208M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.7% | +9 points |
| Q2 2026 | -3.9% | +4 points |
| Q1 2026 | -7.3% | +18 points |
| Q4 2025 | 0.2% | +5.5 points |
| Q3 2025 | -8.3% | +1.3 points |
| Q2 2025 | -7.9% | +4.7 points |
| Q1 2025 | -25% | -9.7 points |
| Q4 2024 | -5.3% | +3.8 points |
OFIX's operating margin was 0.7% last quarter, up 9 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over OFIX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over OFIX on profitability, with a higher operating margin.
OFIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$14.1M | -666% |
| Q2 2026 | -$18.9M | -517% |
| Q1 2026 | -$28.3M | -$3.1M |
| Q4 2025 | $16.8M | +20% |
| Q3 2025 | $2.5M | -61% |
| Q2 2025 | $4.5M | +$4.9M |
| Q1 2025 | -$25.1M | +$4M |
| Q4 2024 | $14.1M | +$35.3M |
OFIX's free cash flow was −$44M over the past year, against −$4M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OFIX on cash generation, producing positive trailing cash flow while its opponent burns cash.
OFIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +272K shares |
| 1 year | +3.6% | +1.4M shares |
| 3 years | +108% | +21.4M shares |
OFIX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OFIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.2x | High |
| Q2 2026 | 8.6x | High |
| Q1 2026 | 10.8x | High |
| Q4 2022 | -3.2x | Net Cash |
| Q3 2022 | -3.0x | Net Cash |
| Q2 2022 | -2.6x | Net Cash |
| Q1 2022 | -3.4x | Net Cash |
| Q4 2021 | -4.1x | Net Cash |
OFIX's net debt is about 4.2 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over OFIX on leverage, with a lower net debt burden relative to earnings.
OFIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.9 | Oversold |
| Stochastic | 8.4 | Oversold |
OFIX's weekly RSI is 30 (oversold) and its Stochastic is 8 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OFIX PE vs Healthcare Sector
| Metric | OFIX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
OFIX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OFIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.85 | 22% below |
| 20 week MA | $9.71 | 29% below |
| 50 week MA | $11.4 | 39% below |
| 100 week MA | $13.0 | 47% below |
| 200 week MA | $14.5 | 52% below |
OFIX is in a downtrend: it's below all five of its weekly moving averages, and 52% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over OFIX on trend strength, trading above more of its moving averages.
OFIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $46.0 | $42.6 | -7.5% |
| 2021 | $42.6 | $31.5 | -26% |
| 2022 | $31.5 | $19.3 | -39% |
| 2023 | $19.3 | $13.5 | -30% |
| 2024 | $13.5 | $17.5 | +30% |
| 2025 | $17.5 | $15.2 | -13% |
| 2026 YTD | $15.2 | $6.94 | -54% |
OFIX has finished lower in five of the last six years. It's down 54% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OFIX on returns for 2026, with the stronger performance.